Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non–Small Cell Lung Cancer in the Context of the US Health Care System

IMPORTANCE: In early 2018, durvalumab became the first immunotherapy to be approved for adjuvant treatment of patients with unresectable stage III non–small cell lung cancer (NSCLC) whose cancer has not progressed after definitive chemoradiotherapy. However, the cost-effectiveness and potential econ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Criss, Steven D., Mooradian, Meghan J., Sheehan, Deirdre F., Zubiri, Leyre, Lumish, Melissa A., Gainor, Justin F., Reynolds, Kerry L., Kong, Chung Yin
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2018
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6439842/
https://ncbi.nlm.nih.gov/pubmed/30543349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.5449
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados